MedTrace Logo

An Interaction Study of Ketoconazole/Verapamil Versus AZD1305

NCT00707551 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose is to study whether ketoconazole or verapamil have an effect on how AZD1305 is handled by the body, i.e the absorption, distribution, metabolism and excretion, when administered in combination with AZD1305.

Conditions

  • Healthy

Interventions

DRUG

Ketoconazole

Tablet, administered as repeated doses.

DRUG

Verapamil

Extended Release tablet, administered as repeated doses.

DRUG

AZD1305

Extended Release tablet, administered as a single dose.

Sponsors & Collaborators

Principal Investigators

  • Helen Lunde, MD · AstraZeneca R&D, Mölndal, Sweden

  • Dago Mazur, MD, PhD · PAREXEL International GmbH, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00707551 on ClinicalTrials.gov